Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)

The stock decreased 11.11% or $0.16 during the last trading session, hitting $1.30.

Some buy side analysts are also providing their Analysis on Protalix BioTherapeutics, Inc., where 1 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 0 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (NYSEMKT:PLX)'s shares have the potential to reach a high EPS of -0.09 per share, and a low EPS of -0.13 per share in the current quarter. It closed the session at $0.46 with a volume of 335800 shares. Protalix BioTherapeutics, Inc. got Initiated on 4-Apr-16 where investment firm Rodman & Renshaw Initiated the stock to Buy.

Shares in the company were 2.3% higher at $1.31 pre-bell. In Protalix Biotherapeutics Inc (NYSEMKT:PLX)'s last 12 earnings reports, it has beaten EPS estimates 41% of the time. Stock exchanged hands with the total volume of 10.41 Million shares, as contrast to its average volume of 4.37 Million shares. They now have a Dollars 0.8 price target on the stock. (:PLX). At the time of writing, the First Call consensus price target for the company is $2.60.

Protalix BioTherapeutics, Inc. on 11/09/2016 reported its EPS as $-0.07 with the analysts projecting the EPS of the stock as $-0.1.

Many analysts have provided their estimated foresights on Protalix BioTherapeutics, Inc. The Company's shares are trading 50.76% above their 50-day moving average and 96.84% above their 200-day moving average.

Having a glance at growth estimates of the company, it has current quarter growth estimates of -114.30%. The Company Touched its 52-Week High on Mar 13, 2017 and 52-Week Low on Dec 13, 2016. While it's Return on Investment (ROI) value is 0%.

The company's stock now has 205.32 Million in market capitalization.

While looking at the Stock's Performance, Protalix BioTherapeutics, Inc. now shows a Weekly Performance of 31.19%, where Monthly Performance is 53.76%, Quarterly performance is 376.67%, 6 Months performance is 130.65% and yearly performance percentage is 57.14%. PLX has P/E (Price to Earnings ttm) value of 3.08, Forward P/E of 0, P/C (Price to cash per share) of 0 and Price to Free Cash Flow (P/FCF) value of 0. The Stock has YTD (year to date) performance of 184.44 percent. While revenue estimates for the current year is $8.31M, Protalix Biotherapeutics Inc (NYSEMKT:PLX) setting the highest revenues estimates of $8.62M and indicating lowest revenues at $8M according to agreement of 2 number of analysts.

Related news: